Mark S. Dennis - Concepedia

Author

Mark S. Dennis

Denali Therapeutics (United States)ORCID

Also Known As

Dennis, M., Dennis, Mark, M S Dennis, M. Dennis, M. S. Dennis, M.S. Dennis, Marilyn Dennis, Mark Dennis, Mark S Dennis, Mark S. DENNIS

141

Publications

11.1K

Citations

H-Index

128

Concepts

All Affiliations

Denali Therapeutics (United States)Genesys (United States)PDL BioPharma (United States)Genentech Research & Diagnostic Antibodies (United States)

About

Mark S. Dennis is an author at Denali Therapeutics (United States) specializing in medicine, immunology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	36	5.2K
2	Natural Sciences	14	15	1.6K
3	Engineering	4	4	799
4	Health Sciences	1	1	37
5	Public Health	1	1	114

Mark S. Dennis

Publications

10.9K

Citations

H-Index

Page 1

	Year	Citations
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Jagath R. Junutula, Helga Raab, Suzanna Clark, Nature Biotechnology Medicinal ChemistryImmunocytochemical TechniqueDrug TargetingTherapeutic IndexMedicine	2008	1.3K
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target Yichao Yu, Yin Zhang, Margaret Kenrick, Science Translational Medicine	2011	780
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins Mark S. Dennis, Min Zhang, Miryam Kadkhodayan, Journal of Biological Chemistry	2002	494
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates Yang Yu, Jasvinder K. Atwal, Yin Zhang, Science Translational Medicine	2014	355
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants Nga Bien‐Ly, Yang Yu, Daniela Bumbaca, The Journal of Experimental Medicine ImmunologyBrain ExposureTherapeuticsBrain Tfr LevelsSynaptic Signaling	2014	336
Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys Mihalis S. Kariolis, Robert C. Wells, Jennifer A. Getz, Science Translational Medicine	2020	331
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice Megan Lo, Hok Seon Kim, Raymond K. Tong, Journal of Biological Chemistry	2017	315
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies Y. Joy Yu Zuchero, Xiaocheng Chen, Nga Bien‐Ly, Neuron Blood–brain BarrierMedicineImmunologyAntibody ScreeningBrain-immune Interaction	2015	284
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Mark S. Dennis, William J. Henzel, Robert Pitti, Proceedings of the National Academy of Sciences ImmunologyPharmacotherapyChemical BiologyPlatelet AggregationMolecular Pharmacology	1990	283
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies Liping Sun, Diego Ellerman, Mary Mathieu, Science Translational Medicine	2015	269

Page 1